Author

F. Kommoss

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 3 Approach:experimental assay· 3 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Assay:ChIP-seq· 1 Research Focus:differential expression· 1 Research Focus:gene regulatory network inference· 1

Frequent Co-Authors

A. N. Karnezis· 2 shared B. E. Weissman· 2 shared D. G. Huntsman· 2 shared J. M. Trent· 2 shared P. Pirrotte· 2 shared Y. Wang· 2 shared A. Banito· 1 shared A. Cheng· 1 shared

Activity by Year

2019-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 36 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. N. Karnezis

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Somatic gene delivery for flexible in vivo modeling of high-risk sarcoma

R. Imle, D. Blosel, F. Kommoss, E. Zhao, R. Autry, C. Blume, D. Lupar, L. Schmitt, C. Winter, L. Wagner, S. Placke, M. von Eicke, M. Hertwig, H. Peterziel, I. Oehme, , A. Banito

This paper develops a mouse model for high-risk sarcoma by delivering genetic lesions via electroporation, generating multiple sarcoma types and validating their molecular and therapeutic relevance.

bioRxiv · Jan 30, 2024 · PreprintCancer Biology

Landscape of super-enhancers in small cell carcinoma of the ovary, hypercalcemic type and efficacy of targeting with natural product triptolide

J. D. Lang, W. Selleck, S. Striker, N. A. Hipschman, R. Kofman, A. N. Karnezis, F. K. Kommoss, F. Kommoss, J. R. Wendt, S. J. Facista, W. P. Hendricks, K. A. Orlando, P. Pirrotte, E. A. Raupach, V. L. Zismann, , J. M. Trent

This paper identifies super-enhancer activity in SCCOHT driven by SMARCA4 loss and shows triptolide effectively inhibits tumor growth by targeting TFIIH at super-enhancers.

bioRxiv · Sep 8, 2023Cancer Biology

Arginine depletion through ADI-PEG20 to treat argininosuccinate synthase deficient ovarian cancer, including small cell carcinoma of the ovary, hypercalcemic type

J. X. Ji, D. R. Cochrane, B. Tessier-Cloutier, S. Chen, G. Ho, K. V. Pathak, I. Alcazar, D. Farnell, S. Leung, A. Cheng, C. Chow, S. Colborne, G. Luca Negri, F. Kommoss, A. N. Karnezis, , D. G. Huntsman

This paper identifies ASS1 deficiency in rare ovarian cancers and shows that ADI-PEG20 inhibits tumor growth in ASS1-deficient models.

bioRxiv · Nov 17, 2019 · PreprintCancer Biology